Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

Fetal/Neonatal Morbidity and Mortality).

Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.

MICARDIS is contraindicated in patients who are hypersensitive to any of their components.

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those receiving high doses of diuretics), symptomatic hypotension may occur after initiation of MICARDIS therapy. This condition should be corrected prior to administration of MICARDIS tablets, and treatment should start under close medical supervision.

The most common adverse events occurring with MICARDIS tablets monotherapy at a rate of 1% and greater than placebo, respectively, were: upper respiratory tract infection (URTI) (7%, 6%), back pain (3%, 1%), sinusitis (3%, 2%), diarrhea (3%, 2%), and pharyngitis (1%, 0%).

Please visit http://www.micardis.com for full Prescribing Information for MICARDIS.

References:

1 The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-59.

2 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53

3 The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients; The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment study In ACE Intolerant Subjects with Cardiovascular disease

4 Facts and Figures: World Health Report 2003. World Health Organization

5 The
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... ( www.curemark.com ), a drug research and development company focused ... & Renshaw Annual Global Investment Conference held September 12-15 in ... 5,000 investors and other attendees.   "Curemark was ... present at the conference, which included a full roster of ...
... OmniComm Systems, Inc. (OTC Bulletin Board: ... and services announced that it will be hosting the ... Beach Resort in Fort Lauderdale, Florida from November 03-05, ... from participating Life Science organizations. The informal ambiance provides ...
Cached Medicine Technology:Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe ... consultations with specialists, physical therapy, and injections , ... mid back and/or lower back pain, Healthpointe has ... injections for herniated discs, disc protrusions and other ... , Healthpointe’s team of renowned surgeons are ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of Treating ... now offering free weekly call in teleconferences each ... to reduce symptoms associated with fibromyalgia including chronic ... fog. , To find out more about ... in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... (MGH) researchers have identified a new molecular pathway that ... This early-stage kidney disease affects 100 million people around ... the kidneys filtering structures. Blocking this pathway could ... slow the process of kidney failure. The research ...
... impact on behavior, studies show , , WEDNESDAY, Dec. 19 (HealthDay ... trillion cells, looking for perhaps only one or a handful ... of new studies says. , The research, conducted with rodents ... , could rewrite the textbooks on just how important individual ...
... a way to use a firefly gene to let them ... against some forms of cancer and its serious complication. ... and leukemia, a form of cancer where it is particularly ... prognosis is generally poor. There is now no widely effective ...
... Helping Latino Nonprofits and Families With Cash,Donation. Photo ... Latino with,HIV., WASHINGTON, Dec. 19 The ... This holiday season, MAYA is giving $10,000 to ... the Latino community.,MAYA will also donate cash to ...
... Health Net of California See Big Increases in ... Surveyor from HealthLeaders-InterStudy Reveals ... NASHVILLE, Tenn., Dec. 19 HealthLeaders-InterStudy, the,leading ... managed,care enrollment from January 2007 to July 2007 ...
... volunteer John,Cleland has run four marathons, but the race ... Diagnosed with the disease as a college,undergraduate, Cleland underwent ... punishing rounds of chemotherapy followed. But when,Cleland,s cancer spread ... Then Cleland,s doctor offered one small ray of ...
Cached Medicine News:Health News:Receptor protein appears to be key in breakdown of kidney filtration 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 3Health News:Brain Cells More Powerful Than You Think 2Health News:Brain Cells More Powerful Than You Think 3Health News:Brain Cells More Powerful Than You Think 4Health News:Firefly genes allow testing of new therapy against lymphoma 2Health News:Firefly genes allow testing of new therapy against lymphoma 3Health News:HIV/AIDS Rate Increases in DC Area Latino Population, Community Lacks Resources 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 3Health News:New Book Looks at Clinical Research from the Patient's Point of View 2Health News:New Book Looks at Clinical Research from the Patient's Point of View 3
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: